{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T17:55:00Z","timestamp":1783792500542,"version":"3.55.0"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1097\/inf.0b013e31821c922c","type":"journal-article","created":{"date-parts":[[2011,5,4]],"date-time":"2011-05-04T06:51:19Z","timestamp":1304491879000},"page":"860-865","source":"Crossref","is-referenced-by-count":36,"title":["Safety and Pharmacokinetics of Ribavirin for the Treatment of La Crosse Encephalitis"],"prefix":"10.1097","volume":"30","author":[{"given":"James E.","family":"McJunkin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milap C.","family":"Nahata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily C.","family":"De Los Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Garrett","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Caceres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raheel R.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mouna G.","family":"Chebib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasidharan","family":"Taravath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda L.","family":"Minnich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxane","family":"Carr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine A.","family":"Welch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Whitley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-11-20210202","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1056\/NEJM200103153441103","article-title":"La Crosse encephalitis in children.","volume":"344","author":"McJunkin","year":"2001","journal-title":"N Engl J Med"},{"key":"R2-11-20210202","doi-asserted-by":"crossref","first-page":"509","DOI":"10.4269\/ajtmh.2003.69.509","article-title":"Economic and social impacts of La Crosse encephalitis in western North Carolina.","volume":"69","author":"Utz","year":"2003","journal-title":"Am J Trop Med Hyg"},{"key":"R3-11-20210202","first-page":"2557","article-title":"Textbook of Pediatric Infectious Diseases. 6th ed.","author":"McJunkin","year":"2009"},{"key":"R4-11-20210202","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1177\/0883073807307984","article-title":"Periodic lateralized epileptiform discharges in La Crosse encephalitis, a worrisome subgroup: clinical presentation, electroencephalogram (EEG) patterns, and long-term neurologic outcome.","volume":"23","author":"de los Reyes","year":"2008","journal-title":"J Child Neurol"},{"key":"R5-11-20210202","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0887-8994(01)00337-X","article-title":"La Crosse viral encephalitis mimics herpes simplex viral encephalitis.","volume":"25","author":"Sokol","year":"2001","journal-title":"Pediatr Neurol"},{"key":"R6-11-20210202","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1212\/WNL.18.4.369","article-title":"California arbovirus encephalitis in children.","volume":"18","author":"Chun","year":"1968","journal-title":"Neurology"},{"key":"R7-11-20210202","first-page":"187","article-title":"California Serogroup Viruses.","author":"Deering","year":"1983"},{"key":"R8-11-20210202","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1093\/oxfordjournals.aje.a116497","article-title":"Symptomatic La Crosse viral infections in the central nervous system: a study of risk factors in an endemic area.","volume":"136","author":"Woodruff","year":"1992","journal-title":"Am J Epidemiol"},{"key":"R9-11-20210202","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1128\/AAC.33.11.2009","article-title":"Mechanism of La Crosse virus inhibition by ribavirin.","volume":"33","author":"Cassidy","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"R10-11-20210202","article-title":"Investigational drug brochure: intravenous ribavirin IND 9076.","year":"2001"},{"key":"R11-11-20210202","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/infdis\/153.3.489","article-title":"Ribavirin therapy for Hantaan virus infection in suckling mice.","volume":"153","author":"Huggins","year":"1986","journal-title":"J Infect Dis"},{"key":"R12-11-20210202","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1093\/infdis\/164.6.1119","article-title":"Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome.","volume":"164","author":"Huggins","year":"1991","journal-title":"J Infect Dis"},{"key":"R13-11-20210202","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1128\/AAC.37.3.532","article-title":"Safety tolerance and pharmacokinetics of systemic ribavirin in children with human immunodeficiency virus infection.","volume":"37","author":"Connor","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"R14-11-20210202","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1542\/peds.99.2.261","article-title":"Treatment of severe cases of La Crosse encephalitis with intravenous ribavirin following diagnosis by brain biopsy.","volume":"99","author":"McJunkin","year":"1997","journal-title":"Pediatrics"},{"key":"R15-11-20210202","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1128\/AAC.24.5.696","article-title":"Sensitive radioimmunoassay for the broad-spectrum antiviral agent ribavirin.","volume":"24","author":"Austin","year":"1983","journal-title":"Antimicrob Agents Chemother"},{"key":"R16-11-20210202","article-title":"Wechsler Intelligence Scale for Children. 3rd ed.","author":"Wechsler","year":"1991"},{"key":"R17-11-20210202","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1743-422X-5-25","article-title":"La Crosse virus infectivity, pathogenesis, and immunogenicity in mice and monkeys.","volume":"5","author":"Bennett","year":"2008","journal-title":"Virol J"},{"key":"R19-11-20210202","first-page":"371","article-title":"Clinical Pharmacokinetics. 4th ed.","author":"Pai","year":"2008"},{"key":"R20-11-20210202","first-page":"40","article-title":"Expanded genetanicin volume of distribution in patients with indicators of malnutrition.","volume":"9","author":"Zarowitz","year":"1990","journal-title":"Clin Pharm"},{"key":"R21-11-20210202","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1128\/AAC.45.3.943-945.2001","article-title":"High-dose intravenous ribavirin therapy for subacute sclerosing panencephalitis.","volume":"45","author":"Hosoya","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"R22-11-20210202","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1128\/AAC.00356-07","article-title":"In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.","volume":"51","author":"Gowen","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"R23-11-20210202","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1592\/phco.20.15.1216.34582","article-title":"Intravenous ribavirin and hyperammonemia in an immunocompromised patient infected with adenovirus.","volume":"20","author":"Bertrand","year":"2000","journal-title":"Pharmacotherapy"},{"key":"R24-11-20210202","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1177\/135965359900400404","article-title":"Intravenous ribavirin for hantavirus pulmonary syndrome: safety and tolerance during 1 year of open-label experience. Ribavirin Study Group.","volume":"4","author":"Chapman","year":"1999","journal-title":"Antivir Ther"},{"key":"R26-11-20210202","first-page":"344","article-title":"Fatal lactic acidosis and pancreatitis associated with ribavirin and didanosine therapy.","volume":"13","author":"Butt","year":"2003","journal-title":"AIDS Read"},{"key":"R27-11-20210202","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1177\/135965350501000304","article-title":"Incidence and risk factors for mitochondrial toxicity in treated HIV\/HCV-coinfected patients.","volume":"10","author":"Laguno","year":"2005","journal-title":"Antivir Ther"},{"key":"R28-11-20210202","first-page":"169","article-title":"Ribavirin: A Broad Spectrum Antiviral Agent.","author":"Stephen","year":"1980"},{"key":"R29-11-20210202","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/jmv.1890200308","article-title":"Therapeutic effect of the antiviral agent ribavirin in Jun\u00edn virus infection of primates.","volume":"20","author":"Weissenbacher","year":"1986","journal-title":"J Med Virol"},{"key":"R30-11-20210202","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1128\/AAC.29.3.521","article-title":"Effect of ribavirin and tributylribavirin on argentine hemorrhagic fever (Jun\u00edn virus) in guinea pigs.","volume":"29","author":"Kenyon","year":"1986","journal-title":"Antimicrob Agents Chemother"},{"key":"R33-11-20210202","doi-asserted-by":"crossref","first-page":"4631","DOI":"10.1128\/AAC.48.12.4631-4635.2004","article-title":"Pharmacokinetics and effects of ribavirin following intraventricular administration for treatment of subacute sclerosing panencephalitis.","volume":"48","author":"Hosoya","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"R34-11-20210202","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1128\/AAC.35.7.1448","article-title":"Aerosol and intraperitoneal administration of ribavirin and ribavirin triacetate: pharmacokinetics and protection of mice against intracerebral infection with influenza A\/WSN virus.","volume":"35","author":"Gilbert","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"R35-11-20210202","doi-asserted-by":"crossref","first-page":"807","DOI":"10.3201\/eid0705.017506","article-title":"First isolation of La Crosse virus from naturally infected Aedes albopictus.","volume":"7","author":"Gerhardt","year":"2001","journal-title":"Emerg Infect Dis"},{"key":"R36-11-20210202","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.mehy.2008.05.043","article-title":"The use of oral ribavirin in the management of La Crosse viral infections.","volume":"72","author":"Haddow","year":"2009","journal-title":"Med Hypotheses"},{"key":"R38-11-20210202","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1128\/AAC.01579-07","article-title":"Oseltamivir-ribavirin combination therapyfor highly pathogenic H5N1 influenza infection in mice.","volume":"52","author":"Ilyushina","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"R39-11-20210202","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1128\/AAC.01012-08","article-title":"Effects of double-combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and mice.","volume":"53","author":"Smee","year":"2009","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00006454-201110000-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T15:48:28Z","timestamp":1686066508000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201110000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0b013e31821c922c","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}